Actively Recruiting
Tirzepatide vs Liraglutide in Bone
Led by National and Kapodistrian University of Athens · Updated on 2026-01-21
72
Participants Needed
1
Research Sites
83 weeks
Total Duration
On this page
Sponsors
N
National and Kapodistrian University of Athens
Lead Sponsor
L
Laikο General Hospital, Athens
Collaborating Sponsor
AI-Summary
What this Trial Is About
This prospective cohort study investigates the effects of tirzepatide versus liraglutide on bone turnover markers and body composition in adults with class 3 obesity, characterised by Body Mass Index (BMI) ≥40 kg/m². Participants will be followed for 6 months with assessments at baseline, 3 and 6. The primary outcome is the change in bone resorption marker C-terminal telopeptide of type I collagen (CTX) at 3 months. Secondary outcomes include changes in body weight, BMI, bone mineral density (BMD), and body composition. The study aims to clarify the differential impact of weight loss achieved through tirzepatide versus liraglutide on bone metabolism and body composition in adults with obesity.
CONDITIONS
Official Title
Tirzepatide vs Liraglutide in Bone
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged between 30 and 65 years
- Body Mass Index (BMI) of 40 kg/m² or higher
You will not qualify if you...
- Diagnosis of type 1 or type 2 diabetes mellitus
- Chronic kidney disease
- Liver failure
- Heart failure
- Presence of any malignancy
- Previous bariatric or gastrointestinal surgery involving intestinal bypass
- Uncontrolled hypo- or hyperthyroidism
- Uncontrolled hypo- or hyperparathyroidism
- Pregnancy or lactation
- Recent fracture within the past 2 years
- Rare metabolic bone diseases such as Paget's disease, fibrous dysplasia, or osteopetrosis
- Inflammatory arthritis
- Use of medications affecting bone markers (e.g., bone-anabolic agents, antiresorptive agents, antiandrogenic agents, vitamin K antagonists, antipsychotics, contraceptives, oral glucocorticoids, methotrexate, thiazides, aromatase inhibitors)
- Hemolytic anemia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Laiko General Hospital
Athens, Attica, Greece, 11527
Actively Recruiting
Research Team
M
Maria Evangelia Koloutsou, Endocrinology Resident
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here